AstraZeneca: to present 'ground-breaking' lung cancer data.

(CercleFinance.com) - AstraZeneca plans to present "ground-breaking results" from two pivotal trials in non-small cell lung cancer tomorrow at the ESMO Asia Congress in Singapore.


The drugmaker will unveil two phase III on Tagrisso as 1st-line therapy in locally advanced or metastatic EGFR mutation-positive NSCLC, which accounts for 30% to 40% of all NSCLC cases in Asian patients.

The firm will also showcase results of a trial on Imfinzi in locally advanced (Stage III), unresectable NSCLC, an earlier stage of the disease for which treatment options are limited.

Copyright (c) 2017 CercleFinance.com. All rights reserved.